Explanation for high death rates in minorities with WuFlu
Nonwhite men with G6PD genetic deficiency are very susceptible to severe reactions to certain medicines in coronavirus treatment
This blog entry of picrel appears in the middle of the website shown below:
https://europa.is/global/coronacrisis/risky-vaccination-experiments-dr-wodarg-and-dr-yeadon-eu-petition/
https://archive.md/JBzuE
The high death rates are due to "glucose-6-dehydrogenase deficiency, or 'G6PD deficiency', one of the most common genetic peculiarities, which can lead to threatening haemolysis (dissolution of red blood cells), mainly in men, when certain drugs or chemicals are taken," especially hydroxychloroquine and acetylsalicylic acid (aspirin).
German pulmonologist and former member of the German Parliament Dr. med. Wolfgang Wodarg writes that, "The G6PD deficiency then leads to a disruption of the biochemical processes in the red blood cells and – depending on the dose – to mild to life-threatening haemolysis. The debris of the burst erythrocytes subsequently leads to microemboli, which block small vessels throughout the organs." … "This enzyme deficiency "occurs in many regions of Africa in 20 – 30% of the population. It is … one of the most common genetic peculiarities, which can lead to threatening haemolysis (dissolution of red blood cells), mainly in men, when certain drugs or chemicals are taken."
"This hereditary trait is particularly common among ethnic groups living in areas with malaria. The modified G6PD gene offers advantages in the tropics. It makes its carriers resistant to malaria pathogens. However, G6PD deficiency is also dangerous if those affected come into contact with certain substances found in, for example, field beans, currants, peas and a number of medicines. These include acetylsalicylic acid, metamizole, sulfonamides, vitamin K, naphthalene, aniline, malaria drugs and nitrofurans."
Most studies don't take the G6PD deficiency into account when studying HCQ and coronavirus: "There are now hundreds of trials worldwide, planned or ongoing by different sponsors, in which HCQ is used alone or together with other drugs. When I looked at some large studies to see if patients with G6PD deficiency were excluded, I found no evidence of this in most study plans. In the USA, for example, a large multi-center study with 4,000 volunteers from healthy medical staff is being prepared. Here, however, the term “hypersensitivity” is only used in general terms, as is the case with all drugs with regard to allergic reactions. In a chloroquine/hydroxychloroquine study by Oxford University (NCT04303507) with a planned 40,000 participants, the risk of G6PD deficiency is also not mentioned. In another large study by the Pentagon, though, there is an explicit warning to exclude G6PD deficiency patients from the study."